



PATENT

I hereby certify that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to the Commissioner for Patents, Washington, DC 20231.

June 8, 2001

Date

Monica Steinborn

Monica Steinborn

#4

Plunkett

9/4/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Marc W. Retter and Gary R. Fanger
Application No. : 09/827,271
Filed : April 4, 2001
For : COMPOSITIONS AND METHODS FOR THE THERAPY AND
DIAGNOSIS OF OVARIAN CANCER
Docket No. : 210121.462C6

Commissioner for Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:


In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached form PTO-1449 (copies of the cited references are enclosed). As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.



Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC



Jane E. R. Potter
Jane E. R. Potter
Registration No. 33,332

JEP:mls

Enclosures:

- Postcard
- Form PTO-1449
- Form PTO/SB/21
- Cited References (10)

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.462C6	APPLICATION NO. 09/827,271
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS		Marc W. Retter and Gary R. Fanger	
		FILING DATE		GROUP ART UNIT	
		April 4, 2001			

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES
	AB						NO

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AC	Bookman et al., "Biological therapy of ovarian cancer: Current directions," <i>Seminars in Oncology</i> , 25(3):381-396, 1998.
AD	Gillespie et al., "Mage, Bage and Gage: Tumour antigen expression in benign and malignant ovarian tissue," <i>British Journal of Cancer</i> , 78(6):816-821, September, 1998.
AE	Heller et al., "Discovery and analysis of inflammatory disease-related genes using cDNA microarrays," <i>Proc. Natl. Acad. Sci. USA</i> 94:2150-2155, March, 1997.
AF	Ishikawa et al., "Prediction of the coding sequence of unidentified human genes. The complete sequence of 100 new cDNA clones from brain which can code for large proteins in vitro," <i>DNA Res.</i> , 5:169-176, 1998.
AG	Jin et al., "Human T cell leukemia virus type 1 oncoprotein tax targets the human mitotic checkpoint protein MAD1," <i>Cell</i> 93:81-91, April 3, 1998.
AH	Köhler et al., "Immunotherapy of Ovarian Carcinoma with the Monoclonal Anti-Idiotype Antibody ACA125 – Results of the Phase LB Study," <i>Gebrutshilfe und Fraenheilkunde</i> , 58(4):180-186, April 1998 + (English Abstract).
AI	Ma et al., "Use of encapsulated single chain antibodies for induction of anti-idiotypic humoral and cellular immune responses," <i>Journal of Pharmaceutical Sciences</i> , 87(11):1375-1378, November, 1998.
AJ	Parker et al., "Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains," <i>The Journal of Immunology</i> 152(1):163-175, January 1, 1994.

EXAMINER	DATE CONSIDERED
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).	

FORM PTO-1449
(REV.7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY. DOCKET NO.
210121.462C6APPLICATION NO.
09/827,271

APPLICANTS

Marc W. Retter and Gary R. Fanger

FILING DATE

April 4, 2001

GROUP ART UNIT

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	BB						

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

BC		Peoples et al., "Ovarian cancer-associated lymphocyte recognition of folate binding protein peptides," <i>Annals of Surgical Oncology</i> , 5(8):743-750, December, 1998.
BD		Schena et al., "Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes," <i>Proc. Natl. Acad. Sci.</i> , 93:10614-10619, October, 1996.
BE		
BF		
BG		
BH		
BI		
BJ		

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).